ID   A549.EpoB40
AC   CVCL_4Z15
SY   EpoB40
DR   cancercelllines; CVCL_4Z15
DR   Wikidata; Q54607056
RX   PubMed=12467233;
RX   PubMed=15956256;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_31550; Epothilone B (EpoB).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0023 ! A-549
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 19-12-24; Version: 11
//
RX   PubMed=12467233;
RA   He L.-F., Yang C.-P.H., Horwitz S.B.;
RT   "Mutations in beta-tubulin map to domains involved in regulation of
RT   microtubule stability in epothilone-resistant cell lines.";
RL   Mol. Cancer Ther. 1:3-10(2001).
//
RX   PubMed=15956256; DOI=10.1158/1535-7163.MCT-05-0024;
RA   Yang C.-P.H., Verdier-Pinard P., Wang F., Lippaine-Horvath E., He L.-F.,
RA   Li D.-S., Hofle G., Ojima I., Orr G.A., Horwitz S.B.;
RT   "A highly epothilone B-resistant A549 cell line with mutations in
RT   tubulin that confer drug dependence.";
RL   Mol. Cancer Ther. 4:987-995(2005).
//